Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through September 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $58 million and $43 million respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At September 30, 2010, the Company had cash and cash equivalents of approximately $3 million. Based on its cash flow projections, the Company w
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Spherix Reports Second Quarter Earnings
    5. Tapestry Reports Second Quarter 2007 Results
    6. Callisto Reports on Second-Quarter 2007 Milestones
    7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    11. Biopure Reports on Meeting with the FDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
    (Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    (Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
    (Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
    (Date:7/9/2014)... (July 9, 2014) A retrospective study conducted by ... colleagues reports that among adults with intellectual and developmental ... number of years receiving dental care increased. The findings, ... in Dentistry , may help improve interventions designed to ... , The researchers reviewed the dental records of ...
    (Date:7/9/2014)... , , , , , ... , , , , ... SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , ...
    (Date:7/9/2014)... Medicine of the University of Southern California (USC) ... of the immune system are completely resistant to ... discovery suggests that blocking this immune system component ... hyper-inflammatory diseases such as rheumatoid arthritis and Type ... on June 23 in The Journal of ...
    Breaking Medicine News(10 mins):Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
    ... danger rises if the drugs are used with certain ... -- Antidepressant drugs called selective serotonin reuptake inhibitors (SSRIs), ... the risk of gastrointestinal bleeding, and the threat is ... and similar pain medications at the same time as ...
    ... Nurses Gain Stronger Voice for Patient Care, AUGUSTA, ... Center in Bangor, Maine appears to be over -- ... Registered nurses and hospital officials Thursday night reached ... the nurses say will,substantially enhance their voice in patient ...
    ... TO COMMENT ON THE MARKET FORECAST FOR THE DRUG, ... Ph.D., analyst,at Decision Resources, is available to discuss the ... of Merck,s Isentress, the,first integrase inhibitor drug which blocks ... new cells. Integrase inhibitors are a novel class ...
    ... New products, a growing world,population expected to reach ... the,aging of that population, will push anesthesia drug ... to Anesthesia Drugs: Worldwide Markets, a,new report by ... procedures required anesthetic,administration worldwide in 2006, and Kalorama ...
    ... Stryker Corporation,(NYSE: SYK ) disclosed today ... made an informal inquiry of the Company regarding ... connection with the sale,of medical devices in certain ... Securities and Exchange Commission regarding this,informal investigation. ...
    ... the 118 patients with portal vein thrombosis, noncirrhotic and ... with well tolerated bleed. Cirrhosis and tumor related portal ... Hypercoagulable state as a cause of portal vein thrombosis ... largest number of patients. , A research article to ...
    Cached Medicine News:Health News:Antidepressants Boost GI Bleeding Risk 2Health News:MSNA: Strike Averted - Tentative Pact at EMMC 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:Anesthesia Drugs Market to Grow to $4.3 Billion by 2011 as Populations and Uses for Anesthesia Increase 2Health News:Portal vein thrombosis is common in extraportal vein obstruction 2
    ... throughput reading of entire racks. Its scanner-based image ... and reads in approximately 10 seconds per rack. ... and a list of ActiveX controls is provided ... includes a USB HP Scanner and software. Compatible ...
    ... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
    Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
    ... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
    Medicine Products: